Skip to main content
Premium Trial:

Request an Annual Quote

Just Don't Call It 'Affirmative Action'

While many see Elias Zerhouni's attempt to make his support for new investigators permanent NIH policy a good thing, DrugMonkey doesn't think the issue of who-gets-what is so clear-cut. He says it's the inherent bias in peer review that needs to be changed, and that Band-Aid solutions like the so-called affirmative action favoring young or first-time grant applicants are masking the real problem. "How so? The use of the term 'affirmative action' tells us all we need to know. This brings in the GoodOldWhite(haired)Boyz dogwhistle to assert that New Investigators are rightfully receiving poorer scores and need an artificial leg up," the post says.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.